Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
SOBI.ST Stock Price Chart
Explore Swedish Orphan Biovitrum AB (publ) interactive price chart. Choose custom timeframes to analyze SOBI.ST price movements and trends.
SOBI.ST Company Profile
Discover essential business fundamentals and corporate details for Swedish Orphan Biovitrum AB (publ) (SOBI.ST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
15 Sept 2006
Employees
1.90K
Website
https://www.sobi.comCEO
Guido Oelkers
Description
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
SOBI.ST Financial Timeline
Browse a chronological timeline of Swedish Orphan Biovitrum AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 3 Feb 2026
Upcoming earnings on 23 Oct 2025
Earnings released on 16 Jul 2025
EPS came in at kr 1.83 falling short of the estimated kr 1.87 by -2.14%, while revenue for the quarter reached kr 6.18B , missing expectations by -1.86%.
Earnings released on 29 Apr 2025
EPS came in at kr 2.43 surpassing the estimated kr 2.07 by +17.39%, while revenue for the quarter reached kr 6.47B , beating expectations by +9.06%.
Earnings released on 6 Feb 2025
EPS came in at kr 4.02 surpassing the estimated kr 3.04 by +32.24%, while revenue for the quarter reached kr 7.44B , beating expectations by +21.01%.
Earnings released on 24 Oct 2024
EPS came in at kr 4.31 surpassing the estimated kr 2.36 by +82.63%, while revenue for the quarter reached kr 6.89B , beating expectations by +17.84%.
Earnings released on 16 Jul 2024
EPS came in at kr 0.72 surpassing the estimated kr 0.69 by +4.35%, while revenue for the quarter reached kr 5.44B , missing expectations by -6.98%.
Earnings released on 25 Apr 2024
EPS came in at kr 2.67 surpassing the estimated kr 2.38 by +12.18%, while revenue for the quarter reached kr 6.26B , beating expectations by +8.00%.
Earnings released on 8 Feb 2024
EPS came in at kr 3.21 falling short of the estimated kr 3.71 by -13.48%, while revenue for the quarter reached kr 6.84B , beating expectations by +1.43%.
Earnings released on 30 Oct 2023
EPS came in at kr 0.30 falling short of the estimated kr 0.36 by -16.67%, while revenue for the quarter reached kr 5.17B , beating expectations by +13.55%.
Stock split effective on 28 Aug 2023
Shares were split 523 : 500 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 18 Jul 2023
EPS came in at kr 0.74 falling short of the estimated kr 1.15 by -35.65%, while revenue for the quarter reached kr 4.87B , beating expectations by +10.61%.
Earnings released on 27 Apr 2023
EPS came in at kr 3.40 surpassing the estimated kr 3.37 by +0.89%, while revenue for the quarter reached kr 5.24B , missing expectations by -1.29%.
Earnings released on 8 Feb 2023
EPS came in at kr 4.64 surpassing the estimated kr 4.63 by +0.22%, while revenue for the quarter reached kr 5.99B , beating expectations by +6.29%.
Earnings released on 27 Oct 2022
EPS came in at kr 1.59 surpassing the estimated kr 1.33 by +19.55%, while revenue for the quarter reached kr 4.00B , beating expectations by +1.24%.
Earnings released on 19 Jul 2022
EPS came in at kr 0.86 surpassing the estimated kr 0.62 by +38.71%, while revenue for the quarter reached kr 3.88B , beating expectations by +9.18%.
Earnings released on 28 Apr 2022
EPS came in at kr 3.64 surpassing the estimated kr 2.81 by +29.54%, while revenue for the quarter reached kr 4.93B , beating expectations by +9.45%.
Earnings released on 10 Feb 2022
EPS came in at kr 4.18 surpassing the estimated kr 3.41 by +22.58%, while revenue for the quarter reached kr 4.90B , beating expectations by +2.69%.
Earnings released on 22 Oct 2021
EPS came in at kr 1.59 surpassing the estimated kr 1.30 by +22.31%, while revenue for the quarter reached kr 3.76B , beating expectations by +22.31%.
Earnings released on 21 Jul 2021
EPS came in at kr 0.90 surpassing the estimated kr 0.65 by +38.46%, while revenue for the quarter reached kr 3.21B .
Earnings released on 4 May 2021
EPS came in at kr 2.33 falling short of the estimated kr 2.44 by -4.51%, while revenue for the quarter reached kr 3.66B .
Earnings released on 18 Feb 2021
EPS came in at kr 3.69 surpassing the estimated kr 3.02 by +22.19%, while revenue for the quarter reached kr 4.58B .
Earnings released on 22 Oct 2020
EPS came in at kr 0.93 falling short of the estimated kr 1.07 by -13.08%, while revenue for the quarter reached kr 2.97B .
SOBI.ST Stock Performance
Access detailed SOBI.ST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.